Physician profile
Nikhil Gera
NPI 1568620722
$1,918.09
in general payments reported to CMS, 2019-2025
11 companies · $27.35 in 2025
The $27.35 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $372 · 2023: $847 · 2024: $407 · 2025: $27.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275 · Education: $6.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.85 |
| Education | $6.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $320.92 | 2022-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $319.89 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $309.18 | 2021-2023 | Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $275.87 | 2021-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $268.69 | 2021-2025 | Ingrezza |
| Indivior INC. | $137.75 | 2022-2024 | Perseris |
| Bioxcel Therapeutics, INC. | $121.06 | 2023 | Igalmi |
| Abbvie INC. | $114.25 | 2023-2024 | |
| Eisai INC. | $17.16 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.02 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Gera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.